CTO Clinical Studies Ontology

Example(s):
- CTO Ontology, 2020.
- CTO-NDD Clinical Trial Ontology-Neurodegenerative Diseases (~2016).
- …
Counter-Example(s):
- CDISC.
- SNOWMED.
- PubChem.
See: Domain-Specific Ontology, International Conference on Biomedical Ontologies (ICBO), Clinical Research Ontology.

References

(Lin, Gebel et al., 2021) ⇒ Asiyah Yu Lin, Stephan Gebel, Qingliang Leon Li, Sumit Madan, Johannes Darms, Evan Bolton, Barry Smith, Martin Hofmann-Apitius, Yongqun Oliver He, and Alpha Tom Kodamullil. (2021). “CTO: A Community-Based Clinical Trial Ontology and Its Applications in PubChemRDF and SCAIViewH.” In: Proceedings of the 11th International Conference on Biomedical Ontologies (ICBO) and 10th Workshop on Ontologies and Data in Life Sciences (ODLS).
- ABSTRACT: Driven by the use cases of PubChemRDF and SCAIView, we have developed a first community-based clinical trial ontology (CTO) by following the OBO Foundry principles. CTO uses the Basic Formal Ontology (BFO) as the top level ontology and reuses many terms from existing ontologies. CTO has also defined many clinical trial-specific terms. The general CTO design pattern is based on the PICO framework together with two applications. First, the PubChemRDF use case demonstrates how a drug Gleevec is linked to multiple clinical trials investigating Gleevec’s related chemical compounds. Second, the SCAIView text mining engine shows how the use of CTO terms in its search algorithm can identify publications referring to COVID-19-related clinical trials. Future opportunities and challenges are discussed.
- https://youtu.be/4tmyDN6enuA

https://web.archive.org/web/20200925225307/https://bioportal.bioontology.org/ontologies/CTO
- QUOTE: Clinical Trial Ontology (CTO) is designed to formally represent and integrate all terms used to describe and register the clinical trials. The development of CTO was done as a collaborative project among Fraunhofer SCAI, Germany; University of Michigan; Center for Devices and Radiological Health, FDA; and National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda. Respective related projects are described below: At Fraunhofer SCAI, the work was supported and funded from the EU’s Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 785907 (Human Brain Project SGA2 by the HBP Medical Informatics Platform) and No. 826421 (VirtualBrainCloud), and a Fraunhofer internal funding MAVO project "Human Brain Pharmacome". At University of Michigan, the work was supported by the NIH-NIDDK U2C Project (1U2CDK114886) and a grant from the Michigan Medicine–Peking University Health Sciences Center Joint Institute for Clinical and Translational Research (U063430). At NCBI side, thhe work of QL and EB was supported by the Intramural Research Program of the National Library of Medicine, National Institutes of Health.